1. Home
  2. GFL vs GMAB Comparison

GFL vs GMAB Comparison

Compare GFL & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GFL
  • GMAB
  • Stock Information
  • Founded
  • GFL 2007
  • GMAB 1999
  • Country
  • GFL Canada
  • GMAB Denmark
  • Employees
  • GFL N/A
  • GMAB N/A
  • Industry
  • GFL
  • GMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • GFL
  • GMAB Health Care
  • Exchange
  • GFL Nasdaq
  • GMAB Nasdaq
  • Market Cap
  • GFL 17.5B
  • GMAB 17.4B
  • IPO Year
  • GFL 2020
  • GMAB N/A
  • Fundamental
  • Price
  • GFL $43.68
  • GMAB $30.56
  • Analyst Decision
  • GFL Strong Buy
  • GMAB Strong Buy
  • Analyst Count
  • GFL 10
  • GMAB 6
  • Target Price
  • GFL $57.97
  • GMAB $40.40
  • AVG Volume (30 Days)
  • GFL 1.4M
  • GMAB 2.5M
  • Earning Date
  • GFL 11-05-2025
  • GMAB 11-06-2025
  • Dividend Yield
  • GFL 0.14%
  • GMAB N/A
  • EPS Growth
  • GFL N/A
  • GMAB 132.41
  • EPS
  • GFL 6.65
  • GMAB 25.10
  • Revenue
  • GFL $5,904,199,182.00
  • GMAB $3,845,670,022.00
  • Revenue This Year
  • GFL N/A
  • GMAB $24.92
  • Revenue Next Year
  • GFL $6.56
  • GMAB $15.97
  • P/E Ratio
  • GFL $6.58
  • GMAB $1.21
  • Revenue Growth
  • GFL 27.49
  • GMAB 29.57
  • 52 Week Low
  • GFL $41.29
  • GMAB $17.24
  • 52 Week High
  • GFL $52.00
  • GMAB $33.65
  • Technical
  • Relative Strength Index (RSI)
  • GFL 40.90
  • GMAB 58.36
  • Support Level
  • GFL $42.23
  • GMAB $28.08
  • Resistance Level
  • GFL $43.98
  • GMAB $29.35
  • Average True Range (ATR)
  • GFL 0.97
  • GMAB 0.69
  • MACD
  • GFL -0.01
  • GMAB 0.03
  • Stochastic Oscillator
  • GFL 37.41
  • GMAB 95.93

About GFL GFL Environmental Inc. Subordinate voting shares no par value

GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: